APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tumor Necrosis Factor Receptor Superfamily Member 9

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Outlook and Growth Opportunities 2026

19 December 2025197 pages

Choose your research edition.

Industry ResearchTumor Necrosis Factor Receptor Superfamily Member 9 Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Tumor Necrosis Factor Receptor Superfamily Member 9 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tumor Necrosis Factor Receptor Superfamily Member 9 Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Tumor Necrosis Factor Receptor Superfamily Member 9 Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Tumor Necrosis Factor Receptor Superfamily Member 9 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Tumor Necrosis Factor Receptor Superfamily Member 9 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tumor Necrosis Factor Receptor Superfamily Member 9 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tumor Necrosis Factor Receptor Superfamily Member 9 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Tumor Necrosis Factor Receptor Superfamily Member 9 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Tumor Necrosis Factor Receptor Superfamily Member 9 market include Eli Lilly and Co, Pfizer Inc, Pieris Pharmaceuticals Inc, MacroGenics Inc, Juno Therapeutics Inc, BioInvent International AB, Apogenix GmbH, Alligator Bioscience AB and Agenus Inc, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Tumor Necrosis Factor Receptor Superfamily Member 9 market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tumor Necrosis Factor Receptor Superfamily Member 9 and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tumor Necrosis Factor Receptor Superfamily Member 9 revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Tumor Necrosis Factor Receptor Superfamily Member 9 market.

Tumor Necrosis Factor Receptor Superfamily Member 9 Segment by Company

Eli Lilly and Co

Pfizer Inc

Pieris Pharmaceuticals Inc

MacroGenics Inc

Juno Therapeutics Inc

BioInvent International AB

Apogenix GmbH

Alligator Bioscience AB

Agenus Inc

Tumor Necrosis Factor Receptor Superfamily Member 9 Segment by Type

Ultra-41BBL

PRS-342

ISAS-01

EU-101

Others

Tumor Necrosis Factor Receptor Superfamily Member 9 Segment by Application

Gastric Cancer

Lymphoma

Cervical Cancer

Bladder Cancer

Others

Tumor Necrosis Factor Receptor Superfamily Member 9 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Tumor Necrosis Factor Receptor Superfamily Member 9 status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Tumor Necrosis Factor Receptor Superfamily Member 9 key companies, revenue, market share, and recent developments.

3. To split the Tumor Necrosis Factor Receptor Superfamily Member 9 breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Tumor Necrosis Factor Receptor Superfamily Member 9 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Tumor Necrosis Factor Receptor Superfamily Member 9 significant trends, drivers, influence factors in global and regions.

6. To analyze Tumor Necrosis Factor Receptor Superfamily Member 9 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Necrosis Factor Receptor Superfamily Member 9 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tumor Necrosis Factor Receptor Superfamily Member 9 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Necrosis Factor Receptor Superfamily Member 9.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tumor Necrosis Factor Receptor Superfamily Member 9 industry.

Chapter 3: Detailed analysis of Tumor Necrosis Factor Receptor Superfamily Member 9 company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Tumor Necrosis Factor Receptor Superfamily Member 9 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Tumor Necrosis Factor Receptor Superfamily Member 9 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Trends Table 2. Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Drivers Table 3. Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Opportunities and Challenges Table 4. Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Restraints Table 5. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Share by Company (2021-2026) Table 7. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Key Company Manufacturing Base & Headquarters Table 9. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Company, Product Type & Application Table 10. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Tumor Necrosis Factor Receptor Superfamily Member 9 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Ultra-41BBL Table 15. Significant Companies of PRS-342 Table 16. Significant Companies of ISAS-01 Table 17. Significant Companies of EU-101 Table 18. Significant Companies of Others Table 19. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type (2021-2026) Table 23. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Gastric Cancer Table 25. Significant Companies of Lymphoma Table 26. Significant Companies of Cervical Cancer Table 27. Significant Companies of Bladder Cancer Table 28. Significant Companies of Others Table 29. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application (2021-2026) Table 33. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application (2027-2032) Table 34. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Region (2021-2026) Table 37. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Region (2027-2032) Table 39. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Market Share by Country (2021-2026) Table 42. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Market Share by Country (2027-2032) Table 44. Eli Lilly and Co Company Information Table 45. Eli Lilly and Co Business Overview Table 46. Eli Lilly and Co Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Eli Lilly and Co Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 48. Eli Lilly and Co Recent Development Table 49. Pfizer Inc Company Information Table 50. Pfizer Inc Business Overview Table 51. Pfizer Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Pfizer Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 53. Pfizer Inc Recent Development Table 54. Pieris Pharmaceuticals Inc Company Information Table 55. Pieris Pharmaceuticals Inc Business Overview Table 56. Pieris Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Pieris Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 58. Pieris Pharmaceuticals Inc Recent Development Table 59. MacroGenics Inc Company Information Table 60. MacroGenics Inc Business Overview Table 61. MacroGenics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. MacroGenics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 63. MacroGenics Inc Recent Development Table 64. Juno Therapeutics Inc Company Information Table 65. Juno Therapeutics Inc Business Overview Table 66. Juno Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Juno Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 68. Juno Therapeutics Inc Recent Development Table 69. BioInvent International AB Company Information Table 70. BioInvent International AB Business Overview Table 71. BioInvent International AB Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. BioInvent International AB Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 73. BioInvent International AB Recent Development Table 74. Apogenix GmbH Company Information Table 75. Apogenix GmbH Business Overview Table 76. Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 78. Apogenix GmbH Recent Development Table 79. Alligator Bioscience AB Company Information Table 80. Alligator Bioscience AB Business Overview Table 81. Alligator Bioscience AB Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Alligator Bioscience AB Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 83. Alligator Bioscience AB Recent Development Table 84. Agenus Inc Company Information Table 85. Agenus Inc Business Overview Table 86. Agenus Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Agenus Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 88. Agenus Inc Recent Development Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. Tumor Necrosis Factor Receptor Superfamily Member 9 Product Image Figure 2. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 4. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Ultra-41BBL Image Figure 8. PRS-342 Image Figure 9. ISAS-01 Image Figure 10. EU-101 Image Figure 11. Others Image Figure 12. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type (2021-2032) Figure 15. Gastric Cancer Image Figure 16. Lymphoma Image Figure 17. Cervical Cancer Image Figure 18. Bladder Cancer Image Figure 19. Others Image Figure 20. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application (2021-2032) Figure 23. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value (2021-2032) & (US$ Million) Figure 26. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value (2021-2032) & (US$ Million) Figure 28. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value (2021-2032) & (US$ Million) Figure 32. South America Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • Ultra-41BBL
  • PRS-342
  • ISAS-01
  • EU-101
  • Others
Applications
  • Gastric Cancer
  • Lymphoma
  • Cervical Cancer
  • Bladder Cancer
  • Others
Companies covered
  • Eli Lilly and Co
  • Pfizer Inc
  • Pieris Pharmaceuticals Inc
  • MacroGenics Inc
  • Juno Therapeutics Inc
  • BioInvent International AB
  • Apogenix GmbH
  • Alligator Bioscience AB
  • Agenus Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Tumor Necrosis Factor Receptor Superfamily Member 9 Market Dynamics
  1. 2.1 Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Trends
  2. 2.2 Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Drivers
  3. 2.3 Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Opportunities and Challenges
  4. 2.4 Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Restraints
3 Tumor Necrosis Factor Receptor Superfamily Member 9 Market by Company
  1. 3.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Company Revenue Ranking in 2025
  2. 3.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue by Company (2021-2026)
  3. 3.3 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Company Ranking (2024-2026)
  4. 3.4 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Company Manufacturing Base and Headquarters
  5. 3.5 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Company Product Type and Application
  6. 3.6 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Tumor Necrosis Factor Receptor Superfamily Member 9 Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Tumor Necrosis Factor Receptor Superfamily Member 9 Market by Type
  1. 4.1 Tumor Necrosis Factor Receptor Superfamily Member 9 Type Introduction
  2. 4.1.1 Ultra-41BBL
  3. 4.1.2 PRS-342
  4. 4.1.3 ISAS-01
  5. 4.1.4 EU-101
  6. 4.1.5 Others
  7. 4.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Type
  8. 4.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Type (2021-2032)
  10. 4.2.3 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type (2021-2032)
5 Tumor Necrosis Factor Receptor Superfamily Member 9 Market by Application
  1. 5.1 Tumor Necrosis Factor Receptor Superfamily Member 9 Application Introduction
  2. 5.1.1 Gastric Cancer
  3. 5.1.2 Lymphoma
  4. 5.1.3 Cervical Cancer
  5. 5.1.4 Bladder Cancer
  6. 5.1.5 Others
  7. 5.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Application
  8. 5.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Application (2021-2032)
  10. 5.2.3 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application (2021-2032)
6 Tumor Necrosis Factor Receptor Superfamily Member 9 Regional Value Analysis
  1. 6.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Region (2021-2032)
  3. 6.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Region: 2021-2026
  4. 6.2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value (2021-2032)
  7. 6.3.2 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value (2021-2032)
  10. 6.4.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value (2021-2032)
  16. 6.6.2 South America Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Country, 2025 VS 2032
7 Tumor Necrosis Factor Receptor Superfamily Member 9 Country-level Value Analysis
  1. 7.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Country (2021-2032)
  3. 7.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Country (2021-2026)
  4. 7.2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Tumor Necrosis Factor Receptor Superfamily Member 9 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eli Lilly and Co
  2. 8.1.1 Eli Lilly and Co Company Information
  3. 8.1.2 Eli Lilly and Co Business Overview
  4. 8.1.3 Eli Lilly and Co Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eli Lilly and Co Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  6. 8.1.5 Eli Lilly and Co Recent Developments
  7. 8.2 Pfizer Inc
  8. 8.2.1 Pfizer Inc Company Information
  9. 8.2.2 Pfizer Inc Business Overview
  10. 8.2.3 Pfizer Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  12. 8.2.5 Pfizer Inc Recent Developments
  13. 8.3 Pieris Pharmaceuticals Inc
  14. 8.3.1 Pieris Pharmaceuticals Inc Company Information
  15. 8.3.2 Pieris Pharmaceuticals Inc Business Overview
  16. 8.3.3 Pieris Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pieris Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  18. 8.3.5 Pieris Pharmaceuticals Inc Recent Developments
  19. 8.4 MacroGenics Inc
  20. 8.4.1 MacroGenics Inc Company Information
  21. 8.4.2 MacroGenics Inc Business Overview
  22. 8.4.3 MacroGenics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (2021-2026)
  23. 8.4.4 MacroGenics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  24. 8.4.5 MacroGenics Inc Recent Developments
  25. 8.5 Juno Therapeutics Inc
  26. 8.5.1 Juno Therapeutics Inc Company Information
  27. 8.5.2 Juno Therapeutics Inc Business Overview
  28. 8.5.3 Juno Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Juno Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  30. 8.5.5 Juno Therapeutics Inc Recent Developments
  31. 8.6 BioInvent International AB
  32. 8.6.1 BioInvent International AB Company Information
  33. 8.6.2 BioInvent International AB Business Overview
  34. 8.6.3 BioInvent International AB Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (2021-2026)
  35. 8.6.4 BioInvent International AB Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  36. 8.6.5 BioInvent International AB Recent Developments
  37. 8.7 Apogenix GmbH
  38. 8.7.1 Apogenix GmbH Company Information
  39. 8.7.2 Apogenix GmbH Business Overview
  40. 8.7.3 Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  42. 8.7.5 Apogenix GmbH Recent Developments
  43. 8.8 Alligator Bioscience AB
  44. 8.8.1 Alligator Bioscience AB Company Information
  45. 8.8.2 Alligator Bioscience AB Business Overview
  46. 8.8.3 Alligator Bioscience AB Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Alligator Bioscience AB Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  48. 8.8.5 Alligator Bioscience AB Recent Developments
  49. 8.9 Agenus Inc
  50. 8.9.1 Agenus Inc Company Information
  51. 8.9.2 Agenus Inc Business Overview
  52. 8.9.3 Agenus Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Agenus Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  54. 8.9.5 Agenus Inc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst